Advertisement
CLOV vs HUM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLOV is a Buy and HUM is a StrongBuy.
CLOV's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CLOV turned positive on October 20, 2026. Looking at past instances where CLOV's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 55 cases where CLOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CLOV as a result. In 57 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
CLOV moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLOV advanced for three days, in 220 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 148 of 196 cases where CLOV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLOV's P/B Ratio (6.677) is slightly higher than the industry average of (3.582). P/E Ratio (-118.250) is within average values for comparable stocks, (130.390). CLOV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.970) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating fairly steady price growth. CLOV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
HUM in upward trend: price rose above 50-day moving average on October 02, 2026
HUM moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 54 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on HUM as a result. In 51 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for HUM just turned positive on October 05, 2026. Looking at past instances where HUM's MACD turned positive, the stock continued to rise in 34 of 49 cases over the following month. The odds of a continued upward trend are 69%.
The 10-day moving average for HUM crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +3.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 218 of 347 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 174 of 239 cases where HUM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for HUM moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 22 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 64 cases where HUM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
HUM broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.631) is normal, around the industry mean (3.582). P/E Ratio (39.417) is within average values for comparable stocks, (130.390). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CLOV | HUM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 91 | |
SMR RATING 1..100 | 92 | 98 | |
PRICE GROWTH RATING 1..100 | 37 | 4 | |
P/E GROWTH RATING 1..100 | 47 | 6 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLOV's Valuation (8) in the null industry is significantly better than the same rating for HUM (83) in the Managed Health Care industry. This means that CLOV’s stock grew significantly faster than HUM’s over the last 12 months.
HUM's Profit vs Risk Rating (91) in the Managed Health Care industry is in the same range as CLOV (100) in the null industry. This means that HUM’s stock grew similarly to CLOV’s over the last 12 months.
CLOV's SMR Rating (92) in the null industry is in the same range as HUM (98) in the Managed Health Care industry. This means that CLOV’s stock grew similarly to HUM’s over the last 12 months.
HUM's Price Growth Rating (4) in the Managed Health Care industry is somewhat better than the same rating for CLOV (37) in the null industry. This means that HUM’s stock grew somewhat faster than CLOV’s over the last 12 months.
HUM's P/E Growth Rating (6) in the Managed Health Care industry is somewhat better than the same rating for CLOV (47) in the null industry. This means that HUM’s stock grew somewhat faster than CLOV’s over the last 12 months.
| CLOV | HUM | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 66% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 65% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 64% |
| Advances ODDS (%) | 14 days ago 81% | 3 days ago 63% |
| Declines ODDS (%) | 1 day ago 85% | 1 day ago 66% |
| BollingerBands ODDS (%) | N/A | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 76% | 3 days ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLOV’s FA Score shows that 1 FA rating(s) are green while HUM’s FA Score has 2 green FA rating(s).
- CLOV’s FA Score: 1 green, 4 red.
- HUM’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLOV’s TA Score shows that 6 TA indicator(s) are bullish while HUM’s TA Score has 6 bullish TA indicator(s).
- CLOV’s TA Score: 6 bullish, 1 bearish.
- HUM’s TA Score: 6 bullish, 4 bearish.
Price Growth
CLOV (@Managed Health Care) experienced а +1.07% price change this week, while HUM (@Managed Health Care) price change was -2.60% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was +2.49%. For the same industry, the average monthly price growth was +10.42%, and the average quarterly price growth was +42.97%.
Reported Earning Dates
CLOV is expected to report earnings on Nov 04, 2026.
HUM is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Managed Health Care (+2.49% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
Advertisement
CLOV and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLOV has been loosely correlated with ALHC. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CLOV jumps, then ALHC could also see price increases.
| Ticker / NAME | Correlation To CLOV | 1D Price Change % | ||
|---|---|---|---|---|
| CLOV | 100% | -1.05% | ||
| ALHC - CLOV | 35% Loosely correlated | -0.12% | ||
| OSCR - CLOV | 31% Poorly correlated | -0.39% | ||
| PGNY - CLOV | 23% Poorly correlated | +2.39% | ||
| CNC - CLOV | 18% Poorly correlated | +1.42% | ||
| HUM - CLOV | 10% Poorly correlated | -1.05% | ||
More | ||||
HUM and
Correlation & Price change
A.I.dvisor indicates that over the last year, HUM has been closely correlated with UNH. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if HUM jumps, then UNH could also see price increases.